Coherus (CHRS) was bullish today after the FDA approved its UDENYCA cancer therapy. The stock was up 7.11% towards the latter end of the session on high volume. Another stock that received positive FDA news was AcelRX Pharmaceuticals (ACRX), which gained over 15% after the FDA approved its DSUVIA pain medication. Trevena (TRVN) was not so fortunate, losing over -30% after the FDA decided against approving its Oliceridine drug. Here’s a recap of what happened.